^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CRL4-CRBN E3 ubiquitin ligase modulator

    Related drugs:
    23h
    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Mayo Clinic | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
    7d
    Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: May 2026 --> Jul 2026
    Trial initiation date
    |
    cyclophosphamide • topotecan • Qarziba (dinutuximab beta) • iberdomide (CC-220) • Unituxin (dinutuximab) • Leukine (sargramostim)
    8d
    Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, University of Pittsburgh | N=30 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Opdivo (nivolumab) • golcadomide (CC-99282)
    15d
    Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gazyva (obinutuzumab) • golcadomide (CC-99282)
    16d
    A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)
    P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    golcadomide (CC-99282)
    19d
    EXCALIBER: Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=939, Active, not recruiting, Celgene | Trial primary completion date: Mar 2026 --> Nov 2027
    Trial primary completion date
    |
    bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220)
    28d
    Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=88, Recruiting, Alliance for Clinical Trials in Oncology | Suspended --> Recruiting
    Enrollment open
    |
    dexamethasone • Blenrep (belantamab mafodotin-blmf) • iberdomide (CC-220)
    1m
    ICON: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (clinicaltrials.gov)
    P2, N=60, Recruiting, Amsterdam UMC, location VUmc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • carfilzomib • iberdomide (CC-220)
    1m
    CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=466, Active, not recruiting, Celgene | Trial completion date: Feb 2028 --> Jul 2028
    Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • dexamethasone • iberdomide (CC-220)
    1m
    IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation. (PubMed, J Gastroenterol Hepatol)
    IKZF3 drives GC progression and oxaliplatin resistance by activating PI3K/AKT/mTOR signaling. It is a potential prognostic biomarker and therapeutic target, supporting further development of LY294002 and Iberdomide for GC treatment.
    Journal
    |
    IKZF3 (IKAROS Family Zinc Finger 3)
    |
    oxaliplatin • LY294002 • iberdomide (CC-220)
    2ms
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    clonoSEQ
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    2ms
    Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    cyclophosphamide • topotecan • Qarziba (dinutuximab beta) • iberdomide (CC-220) • Unituxin (dinutuximab) • Leukine (sargramostim)